Skip to main content

Table 1 Characteristics of the study population overall and by Aboriginal status, NSW Cancer Registry 2000–2008

From: After accounting for competing causes of death and more advanced stage, do Aboriginal and Torres Strait Islander peoples with cancer still have worse survival? A population-based cohort study in New South Wales

  All (n = 301,356)a Aboriginal (n = 2517)   Non-Aboriginal (n = 260,075)   
  n (%) n (CC %) (MI %)b n (CC %) (MI %)b P valuec
Males 168,326 (55.9) 1313 (52.2) (52.0) 144,109 (55.4) (55.9) Χ2 (1) p = 0.001
Age at diagnosis       Χ2 (8) p < 0.001; MW(z) = 24.3, p < 0.001
 0–39 17,031 (5.7) 263 (10.5) (11.0) 13,398 (5.2) (5.6)  
 40–49 24,538 (8.1) 360 (14.3) (14.9) 19,810 (7.6) (8.1)  
 50–59 50,578 (16.8) 570 (22.7) (22.7) 42,361 (16.3) (16.7)  
 60–64 34,754 (11.5) 358 (14.2) (14.1) 29,730 (11.4) (11.5)  
 65–69 38,813 (12.9) 288 (11.4) (11.3) 33,548 (12.9) (12.9)  
 70–74 40,688 (13.5) 290 (11.5) (11.4) 35,587 (13.7) (13.5)  
 75–79 40,276 (13.4) 210 (8.3) (7.9) 35,701 (13.7) (13.4)  
 80–84 30,592 (10.2) 103 (4.1) (4.0) 27,658 (10.6) (10.2)  
 85+ 24,086 (8.0) 75 (3.0) (2.9) 22,282 (8.6) (8.0)  
Residential remoteness       Χ2 (3) p < 0.001; MW(z) = −30.3, p < 0.001
 Major cities 204,781 (68.0) 1099 (43.7) (43.5) 178,436 (68.6) (68.2)  
 Inner regional 71,652 (23.8) 789 (31.4) (31.2) 60,863 (23.4) (23.7)  
 Outer regional 23,235 (7.7) 493 (19.6) (19.7) 19,467 (7.5) (7.6)  
 Remote/ Very remote 1688 (0.6) 136 (5.4) (5.7) 1309 (0.5) (0.5)  
SEIFA quintile       Χ2 (4) p < 0.001; MW(z) = −23.2,
p < 0.001
 1 (least disadvantaged) 62,971 (20.9) 192 (7.6) (8.1) 54,552 (21.0) (21.0)  
 2 54,345 (18.0) 324 (12.9) (13.0) 47,108 (18.1) (18.1)  
 3 61,341 (20.4) 484 (19.2) (19.4) 52,517 (20.2) (20.4)  
 4 68,943 (22.9) 724 (28.8) (28.3) 59,245 (22.8) (22.8)  
 5 (most disadvantaged) 53,756 (17.8) 793 (31.5) (31.3) 46,653 (17.9) (17.7)  
Stage at diagnosis       Χ2 (3) p < 0.001; MW(z) = −9.0, p < 0.001d
 Localised 124,907 (41.5) 834 (33.1) (34.7) 102,624 (39.5) (41.5)  
 Regional 55,210 (18.3) 578 (23.0) (21.7) 51,572 (19.8) (18.3)  
 Distant 43,660 (14.5) 552 (21.9) (19.8) 42,367 (16.3) (14.4)  
 Unknown 77,579 (25.7) 553 (22.0) (23.8) 63,512 (24.4) (25.8)  
Vital statuse       Χ2 (2) p < 0.001
 Alive 182,801 (60.7) 1172 (46.6) (51.9) 144,476 (55.6) (60.7)  
 Died due to the cancer 89,465 (29.7) 1108 (44.0) (39.6) 87,354 (33.6) (29.6)  
 Died due to other cause 29,090 (9.7) 237 (9.4) (8.5) 28,245 (10.9) (9.7)  
Cancer site       Χ2 (13) p < 0.001
 Stomach 5794 (1.9) 73 (2.9) (2.7) 5544 (2.1) (1.9)  
 Colorectalf 40,288 (13.4) 289 (11.5) (11.0) 37,334 (14.4) (13.4)  
  Colon 25,794 176 (7.0)   23,832 (9.2)   
  Rectum 14,494 113 (4.5)   13,502 (5.2)   
 Liver 3433 (1.1) 50 (2.0) (1.8) 3307 (1.3) (1.1)  
 Pancreas 6729 (2.2) 66 (2.6) (2.3) 6539 (2.5) (2.2)  
 Lung 27,302 (9.1) 392 (15.6) (14.2) 26,161 (10.1) (9.0)  
 Melanoma 30,166 (10.0) 70 (2.8) (4.6) 16,966 (6.5) (10.1)  
 Breastg 37,266 (12.4) 331 (13.2) (13.3) 32,754 (12.6) (12.4)  
 Cervix 2222 (0.7) 63 (2.5) (2.6) 1908 (0.7) (0.7)  
 Uterus 5057 (1.7) 47 (1.9) (1.8) 4620 (1.8) (1.7)  
 Prostate 48,071 (16.0) 226 (9.0) (9.9) 38,712 (14.9) (16.1)  
 Kidney 8333 (2.8) 91 (3.6) (3.6) 7478 (2.9) (2.8)  
 Bladder 6912 (2.3) 43 (1.7) (1.6) 6527 (2.5) (2.3)  
 Ill-defined & unspecified & other rare 11,207 (3.7) 110 (4.4) (4.1) 10,507 (4.0) (3.7)  
 Othersh 68,576 (22.8) 666 (26.5) (26.3) 61,718 (23.7) (22.7)  
  1. CC complete-case, MI multiple imputation, MW Mann-Whitney test, SEIFA socio-economic index for areas (Index of relative socio-economic disadvantage was used in this study).
  2. aIncludes also cases with unknown Aboriginal status.
  3. bPercentage after imputing Aboriginal status.
  4. cΧ2 (df) = Pearson Chi square test (degrees of freedom) was used to test categorical differences and MW(z) = Mann-Whitney test (z value) to test for ordinal differences between Aboriginal and non-Aboriginal people using complete-case data.
  5. dUnknown category was excluded when Mann-Whitney test was conducted.
  6. eVital status at end of follow-up.
  7. fColorectal cancers grouped together and separately for colon (ICD-O-3 C18) and rectum cancers (ICD-O-3 C19-C21).
  8. g Includes 303 cases of male breast cancer.
  9. hAll other cancer sites categorised to this group.